[{"id":"f5056d6b-3ffd-4e44-961f-b461e0552213","acronym":"A051902","url":"https://clinicaltrials.gov/study/NCT04803201","created_at":"2021-03-17T15:57:46.362Z","updated_at":"2025-02-25T14:15:53.168Z","phase":"Phase 2","brief_title":"Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma","source_id_and_acronym":"NCT04803201 - A051902","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME","pipe":" | ","alterations":" TNFRSF8 expression","tags":["PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • azacitidine • cyclophosphamide • etoposide IV • Copiktra (duvelisib) • vincristine • prednisone • Onureg (azacitidine oral) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 10/08/2021","start_date":" 10/08/2021","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-18"},{"id":"14db2cea-3400-48ac-8ad3-0b56fccbb5a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03007030","created_at":"2021-01-18T14:47:28.350Z","updated_at":"2025-02-25T15:42:55.122Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT03007030","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive • TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive • TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 04/05/2017","start_date":" 04/05/2017","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2025-02-10"},{"id":"a5ee75a6-412a-4439-adb0-ad0586456a5d","acronym":"LCCC1637","url":"https://clinicaltrials.gov/study/NCT03264131","created_at":"2021-01-18T16:07:30.882Z","updated_at":"2025-02-25T15:42:58.677Z","phase":"Phase 2","brief_title":"BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma","source_id_and_acronym":"NCT03264131 - LCCC1637","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • prednisone • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 10/11/2018","start_date":" 10/11/2018","primary_txt":" Primary completion: 12/15/2023","primary_completion_date":" 12/15/2023","study_txt":" Completion: 12/15/2028","study_completion_date":" 12/15/2028","last_update_posted":"2025-02-10"},{"id":"fdf5903a-380e-4274-bdb7-c41fd2578d9b","acronym":"NCI-2022-03831","url":"https://clinicaltrials.gov/study/NCT05357794","created_at":"2022-05-03T15:54:14.202Z","updated_at":"2025-02-25T15:35:38.204Z","phase":"Phase 2","brief_title":"Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides","source_id_and_acronym":"NCT05357794 - NCI-2022-03831","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TNFRSF8 • CD4","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/13/2022","start_date":" 10/13/2022","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-10"},{"id":"6fa362b2-89c2-4884-87bd-ac57c53e5ca0","acronym":"E4412","url":"https://clinicaltrials.gov/study/NCT01896999","created_at":"2021-01-29T07:05:03.634Z","updated_at":"2025-02-25T16:36:17.132Z","phase":"Phase 1/2","brief_title":"Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma","source_id_and_acronym":"NCT01896999 - E4412","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-1 • CD4 • LGALS1 • ICOS","pipe":" | ","alterations":" TNFRSF8 expression","tags":["PD-1 • CD4 • LGALS1 • ICOS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Adcetris (brentuximab vedotin) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 03/07/2014","start_date":" 03/07/2014","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-06"},{"id":"b0562de4-83b5-474a-a0ea-2bf447d40f13","acronym":"SGN35-032","url":"https://clinicaltrials.gov/study/NCT04569032","created_at":"2021-01-18T21:49:19.024Z","updated_at":"2025-02-25T16:38:04.380Z","phase":"Phase 2","brief_title":"A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression","source_id_and_acronym":"NCT04569032 - SGN35-032","lead_sponsor":"Seagen Inc.","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Adcetris (brentuximab vedotin) • prednisone • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 11/12/2020","start_date":" 11/12/2020","primary_txt":" Primary completion: 05/09/2024","primary_completion_date":" 05/09/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"e4ee9c8a-52e5-4407-8d69-cf484bfda0df","acronym":"","url":"https://clinicaltrials.gov/study/NCT01352520","created_at":"2021-01-18T05:31:44.732Z","updated_at":"2025-02-25T16:43:37.647Z","phase":"Phase 2","brief_title":"SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)","source_id_and_acronym":"NCT01352520","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive • TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive • TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 79","initiation":"Initiation: 06/01/2011","start_date":" 06/01/2011","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2025-02-05"},{"id":"b4d402cb-9b95-4ade-8b2a-ba008e6e8258","acronym":"","url":"https://clinicaltrials.gov/study/NCT04234048","created_at":"2021-01-18T20:35:42.430Z","updated_at":"2024-07-02T16:34:26.824Z","phase":"Phase 1","brief_title":"Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT04234048","lead_sponsor":"SciTech Development, LLC","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fenretinide nanoparticle (ST-001 nanoFenretinide)"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-06-12"},{"id":"5dee7c2d-c458-4efc-8ddb-50ee403de9bf","acronym":"SGN35-015","url":"https://clinicaltrials.gov/study/NCT01716806","created_at":"2021-01-18T07:28:55.529Z","updated_at":"2024-07-02T16:34:27.249Z","phase":"Phase 2","brief_title":"A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)","source_id_and_acronym":"NCT01716806 - SGN35-015","lead_sponsor":"Seagen Inc.","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Adcetris (brentuximab vedotin) • dacarbazine • bendamustine"],"overall_status":"Completed","enrollment":" Enrollment 131","initiation":"Initiation: 10/31/2012","start_date":" 10/31/2012","primary_txt":" Primary completion: 04/07/2023","primary_completion_date":" 04/07/2023","study_txt":" Completion: 09/12/2023","study_completion_date":" 09/12/2023","last_update_posted":"2024-06-11"},{"id":"b8d254b3-f15e-4c07-822c-72a282b1d8ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT06120504","created_at":"2023-11-07T16:14:29.912Z","updated_at":"2024-07-02T16:35:00.615Z","phase":"Phase 1","brief_title":"A Safety Study of SGN-35T in Adults With Advanced Cancers","source_id_and_acronym":"NCT06120504","lead_sponsor":"Seagen Inc.","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 02/29/2024","start_date":" 02/29/2024","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 04/30/2030","study_completion_date":" 04/30/2030","last_update_posted":"2024-05-28"},{"id":"88d90e77-172d-4510-b158-f4795d53f576","acronym":"CRESCENDO","url":"https://clinicaltrials.gov/study/NCT06072131","created_at":"2023-10-10T15:12:06.102Z","updated_at":"2024-07-02T16:35:00.782Z","phase":"Phase 3","brief_title":"To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL","source_id_and_acronym":"NCT06072131 - CRESCENDO","lead_sponsor":"Acrotech Biopharma Inc.","biomarkers":" ALK • TNFRSF8 • UGT1A1","pipe":" | ","alterations":" TNFRSF8 expression • UGT1A1*1*1","tags":["ALK • TNFRSF8 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Beleodaq (belinostat) • Folotyn (pralatrexate)"],"overall_status":"Recruiting","enrollment":" Enrollment 504","initiation":"Initiation: 10/04/2023","start_date":" 10/04/2023","primary_txt":" Primary completion: 07/01/2030","primary_completion_date":" 07/01/2030","study_txt":" Completion: 11/01/2030","study_completion_date":" 11/01/2030","last_update_posted":"2024-05-27"},{"id":"e704c4fd-c7ac-4597-8954-effccdbd050f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05949944","created_at":"2023-07-20T15:09:21.771Z","updated_at":"2024-07-02T16:35:02.840Z","phase":"Phase 1/2","brief_title":"Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma","source_id_and_acronym":"NCT05949944","lead_sponsor":"Sun Yat-sen University","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive • TNFRSF8 expression • ALK negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • TNFRSF8 expression • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Itari (linperlisib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/15/2023","start_date":" 08/15/2023","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-17"},{"id":"0f098c9e-9aa5-495f-abd0-14af037e624a","acronym":"PACIFIC","url":"https://clinicaltrials.gov/study/NCT04745949","created_at":"2021-02-09T13:53:14.799Z","updated_at":"2024-07-02T16:35:05.970Z","phase":"Phase 2","brief_title":"PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy","source_id_and_acronym":"NCT04745949 - PACIFIC","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Adcetris (brentuximab vedotin) • prednisone • daunorubicin • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/10/2021","start_date":" 05/10/2021","primary_txt":" Primary completion: 08/03/2025","primary_completion_date":" 08/03/2025","study_txt":" Completion: 08/03/2025","study_completion_date":" 08/03/2025","last_update_posted":"2024-05-03"},{"id":"94cf6502-9e21-4ef5-8598-1f6910eb574a","acronym":"CREDIT","url":"https://clinicaltrials.gov/study/NCT05288491","created_at":"2022-03-21T19:55:51.039Z","updated_at":"2024-07-02T16:35:07.004Z","phase":"","brief_title":"A Study of Chinese Adults With Lymphoma","source_id_and_acronym":"NCT05288491 - CREDIT","lead_sponsor":"Takeda","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive • TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive • TNFRSF8 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 10/31/2022","start_date":" 10/31/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-04-30"},{"id":"b856a9ee-5034-47d2-9d2b-077b726e6bdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02744612","created_at":"2021-01-18T13:26:48.184Z","updated_at":"2024-07-02T16:35:07.083Z","phase":"Phase 2","brief_title":"Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma","source_id_and_acronym":"NCT02744612","lead_sponsor":"City of Hope Medical Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Adcetris (brentuximab vedotin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 06/20/2016","start_date":" 06/20/2016","primary_txt":" Primary completion: 03/03/2021","primary_completion_date":" 03/03/2021","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-29"},{"id":"1bee75b3-9c2d-44df-aa38-d77483458e28","acronym":"","url":"https://clinicaltrials.gov/study/NCT02690545","created_at":"2021-01-17T17:19:13.271Z","updated_at":"2024-07-02T16:35:08.192Z","phase":"Phase 1/2","brief_title":"Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL","source_id_and_acronym":"NCT02690545","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TT11 • ATLCAR.CD30 cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/26/2016","start_date":" 08/26/2016","primary_txt":" Primary completion: 08/26/2025","primary_completion_date":" 08/26/2025","study_txt":" Completion: 08/26/2040","study_completion_date":" 08/26/2040","last_update_posted":"2024-04-23"},{"id":"1e1f1982-bd28-4ad1-b264-11dd83d52229","acronym":"","url":"https://clinicaltrials.gov/study/NCT02663297","created_at":"2021-01-18T12:58:42.532Z","updated_at":"2024-07-02T16:35:08.127Z","phase":"Phase 1","brief_title":"Administration of T Lymphocytes for Prevention of Relapse of Lymphomas","source_id_and_acronym":"NCT02663297","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression • ALK negative • TNFRSF8 negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression • ALK negative • TNFRSF8 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TT11 • ATLCAR.CD30 cell therapy"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 07/15/2016","start_date":" 07/15/2016","primary_txt":" Primary completion: 01/15/2021","primary_completion_date":" 01/15/2021","study_txt":" Completion: 01/01/2037","study_completion_date":" 01/01/2037","last_update_posted":"2024-04-23"},{"id":"2b050358-3cb8-4957-b9a8-e85ed3d13514","acronym":"","url":"https://clinicaltrials.gov/study/NCT04083495","created_at":"2021-01-18T19:59:38.796Z","updated_at":"2024-07-02T16:35:08.223Z","phase":"Phase 2","brief_title":"CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma","source_id_and_acronym":"NCT04083495","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV • Belrapzo (bendamustine RTD) • TT11 • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/17/2019","start_date":" 09/17/2019","primary_txt":" Primary completion: 02/23/2028","primary_completion_date":" 02/23/2028","study_txt":" Completion: 08/01/2038","study_completion_date":" 08/01/2038","last_update_posted":"2024-04-23"},{"id":"d5dbb47e-aad4-4309-8d8b-fc01d9f10ce9","acronym":"LCCC 1606-ATL","url":"https://clinicaltrials.gov/study/NCT03602157","created_at":"2021-01-18T17:42:37.765Z","updated_at":"2024-07-02T16:35:08.204Z","phase":"Phase 1","brief_title":"Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL","source_id_and_acronym":"NCT03602157 - LCCC 1606-ATL","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" TNFRSF8 • CCR4","pipe":" | ","alterations":" TNFRSF8 positive • TNFRSF8 expression","tags":["TNFRSF8 • CCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive • TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bendamustine • fludarabine IV • TT11 • ATLCAR.CD30.CCR4 cells"],"overall_status":"Recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 12/12/2018","start_date":" 12/12/2018","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2041","study_completion_date":" 09/30/2041","last_update_posted":"2024-04-23"},{"id":"786063a2-0831-4b28-b56e-5cb86d6097eb","acronym":"RG1713010","url":"https://clinicaltrials.gov/study/NCT01703949","created_at":"2021-01-18T07:24:57.178Z","updated_at":"2024-07-02T16:35:08.657Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma","source_id_and_acronym":"NCT01703949 - RG1713010","lead_sponsor":"University of Washington","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Adcetris (brentuximab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/20/2013","start_date":" 03/20/2013","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-04-19"},{"id":"d1a7b79d-736e-4b7f-8ef7-b4d26c7f7408","acronym":"","url":"https://clinicaltrials.gov/study/NCT05544968","created_at":"2022-09-19T14:56:41.267Z","updated_at":"2024-07-02T16:35:13.132Z","phase":"Phase 1/2","brief_title":"CD30biAb-AATC for CD30+ Malignancies","source_id_and_acronym":"NCT05544968","lead_sponsor":"Medical College of Wisconsin","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD30 biAb-AATC"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-03-22"},{"id":"09898f35-b593-4a51-a7e3-509c8daaecd8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05673785","created_at":"2023-01-06T15:58:43.420Z","updated_at":"2024-07-02T16:35:19.155Z","phase":"Phase 2","brief_title":"A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)","source_id_and_acronym":"NCT05673785","lead_sponsor":"Takeda","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive • TNFRSF8 expression • ALK negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • TNFRSF8 expression • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Adcetris (brentuximab vedotin) • prednisone"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 02/10/2023","start_date":" 02/10/2023","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-02-16"},{"id":"106280da-1c3d-4d99-84ce-6e26d1b4529b","acronym":"REALM","url":"https://clinicaltrials.gov/study/NCT05506774","created_at":"2022-08-18T14:54:55.750Z","updated_at":"2024-07-02T16:35:20.291Z","phase":"","brief_title":"A Study of People With CD30 Positive Lymphoma in China","source_id_and_acronym":"NCT05506774 - REALM","lead_sponsor":"Takeda","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2800","initiation":"Initiation: 02/28/2023","start_date":" 02/28/2023","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-02-07"},{"id":"970d8996-a9a5-499d-9f57-5303ad80c1de","acronym":"","url":"https://clinicaltrials.gov/study/NCT06186986","created_at":"2024-01-02T15:19:20.234Z","updated_at":"2025-02-25T14:52:39.085Z","phase":"Phase 3","brief_title":"CD30 Imaging in Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT06186986","lead_sponsor":"University Medical Center Groningen","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 01/01/2024","start_date":" 01/01/2024","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-01-01"}]